Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Aditxt, Inc. is a publicly traded biotechnology company focused on developing and commercializing technologies that address immune system modulation, diagnostics, and precision health monitoring. The company operates within the biotechnology and life sciences industries, with an emphasis on early disease detection, immune tolerance, and health data-driven insights. Its business model centers on advancing proprietary platforms through internal development, subsidiaries, and strategic partnerships, rather than on commercialized pharmaceutical products at scale.
The company’s primary revenue drivers to date have consisted of research collaborations, technology licensing arrangements, and capital formation activities, as its core programs remain largely in development stages. Aditxt positions itself as a platform innovator seeking to integrate immune monitoring, diagnostics, and therapeutic reprogramming to address chronic disease risk. Founded in 2017, the company has evolved from a single technology focus into a multi-subsidiary structure intended to diversify scientific risk and expand potential commercialization pathways.
Business Operations
Aditxt conducts operations primarily through distinct technology-focused subsidiaries and platform initiatives, including AditxtScore, AditxtReprogramming, and Pearsanta, Inc., each designed to target a different aspect of immune health and disease detection. AditxtScore is focused on immune monitoring and risk assessment using blood-based diagnostics, while AditxtReprogramming is centered on immune tolerance technologies aimed at transplant rejection and autoimmune conditions. Pearsanta, Inc. is oriented toward personalized cancer diagnostics and early detection through molecular profiling.
The company’s operations are primarily research- and development-driven, with activities spanning laboratory research, clinical validation planning, intellectual property management, and regulatory strategy. Aditxt does not currently report large-scale commercial sales and relies on controlled assets, proprietary technologies, and collaborative development models to advance its pipeline. Domestic operations are primarily based in the United States, with select international research and advisory relationships supporting technology development.
Strategic Position & Investments
Aditxt’s strategic direction emphasizes building a portfolio of immune-focused platforms that can be independently advanced, partnered, or spun out as standalone entities. Growth initiatives include advancing diagnostic validation studies, pursuing regulatory pathways for clinical use, and expanding intellectual property coverage. The company has pursued acquisitions and asset contributions to form subsidiaries, including the establishment and expansion of Pearsanta, Inc. as a vehicle for oncology-focused diagnostics.
The company is also exploring emerging sectors such as immune system analytics, precision medicine, and data-enabled diagnostics, positioning itself at the intersection of biotechnology and health data science. While Aditxt has announced various strategic transactions and proposed mergers over time, public disclosures indicate that some transactions remain subject to regulatory approval, financing conditions, or shareholder votes; where outcomes remain unresolved, data is inconclusive based on available public sources.
Geographic Footprint
Aditxt is headquartered in the United States, with its principal executive offices located in California. The company’s core research, administrative, and strategic management activities are primarily domestic, reflecting its status as a U.S.-based biotechnology issuer regulated under U.S. securities laws. Laboratory and development work is conducted through a combination of internal resources and external collaborators.
Internationally, Aditxt maintains a limited but growing footprint through advisory relationships, scientific collaborators, and technology sourcing across North America, Europe, and parts of Asia, depending on the specific subsidiary or platform. While the company does not currently report significant overseas commercial operations, its technologies are designed for global clinical and diagnostic markets, indicating an intent for broader international reach over time.
Leadership & Governance
Aditxt was founded by Amro Albanna, who continues to play a central role in shaping the company’s strategy and long-term vision. Leadership emphasizes platform diversification, disciplined capital deployment, and leveraging scientific partnerships to advance early-stage technologies toward clinical and commercial milestones. The governance structure reflects a development-stage biotechnology company, with active board oversight and executive involvement in subsidiary formation and strategy.
Key executives include:
- Amro Albanna – Co-Founder, Chairman, and Chief Executive Officer
- Hatem Hamdy, MD – Chief Medical Officer
- Additional executive leadership roles have been disclosed intermittently in public filings; however, comprehensive verification of all current senior executives is inconclusive based on available public sources.